United Therapeutics gets a green light for flagship drug
United Therapeutics Corp. says it has received Food and Drug Administration approval for an implantable pump for Remodulin, its flagship pulmonary arterial hypertension drug.
The Maryland drugmaker, which developed the Remodulin pump with Minneapolis-based medical equipment company Medtronic (NYSE: MDT), can now sell the device as another way to deliver its drug intravenously. The company expects the product to be on the market by early next year, according to a spokes man.
The approval offers United…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Sara Gilgore Source Type: news
More News: Biotechnology | Food and Drug Administration (FDA) | Health Management | Hypertension | Medical Devices